CR2 and diffuse large B-cell lymphoma: Similarly, in a set of 54 diffuse large B-cell lymphoma (DLBCL) cases, 28% of CD20+ DLBCL samples lacked detectable CD21, a further 33% had only low expression, and 39% had high expression (Table IIA), confirming that CD21 expression in clinical specimens is indeed variable.